Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
This study has been withdrawn prior to recruitment.
Study NCT00227773 Information provided by National Cancer Institute (NCI)
First Received: September 26, 2005 Last Updated: October 24, 2006
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Gastrointestinal Carcinoid Tumor
Islet Cell Carcinoma
Additional conditions recognized in this trial
Carcinoid Tumor
Carcinoma
Carcinoma, Islet Cell
Gastrointestinal Neoplasms
Malignant Carcinoid Syndrome
Neuroendocrine Tumors
More general conditions related to this trial
Adenocarcinoma
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Gastrointestinal Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Pancreatic Diseases
Pancreatic Neoplasms
Interventions listed in this trial
octreotide acetate
vatalanib
anti-cytokine therapy
antiangiogenesis therapy
biological therapy
endocrine therapy
enzyme inhibitor therapy
growth factor antagonist therapy
hormone therapy
somatostatin analogue therapy
Additional drug interventions recognized in this trial
Enzyme Inhibitors
Mitogens
Octreotide
Somatostatin
More general drug interventions related to this trial
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Gastrointestinal Agents
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Back to top of Main Content
